 DALLAS, March 31, 2021 PRNewswire -- Corporate Highlights Closed four transactions in 2020 deploying 34.8 million; additional 8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an all-time high of 206.0 million, accompanied by strong credit trends Closed a 9.0 million transaction in March 2021, deploying 7.1 million Received two milestone payments from Cara Therapeutics totaling 5.0 million, with SWK retaining 3.0 million and the other 2.0 million being remitted to Enteris prior owner. Specialty Finance Segment Highlights: For the fourth quarter of 2020, finance portfolio realized yield was 16.6, compared to 20.4 for the fourth quarter of 2019 For the fourth quarter of 2020, finance portfolio effective yield was 13.8, a 60 bps increase compared with 13.2 in the fourth quarter of 2019 Income producing assets increased 17.6 year over year to 206.0 million as of December 31, 2020 Total revenue for the quarter ended December 31, 2020 was 10.9 million, a 16.0 increase from 9.4 million for the quarter ended December 31, 2019 Core specialty finance business generated adjusted non-GAAP net income of 23.3 million For the fiscal year 2020, SWK earned an 11.9 adjusted return on tangible financing book value December 31, 2020 tangible financing book value per share was 15.84, a 7.5 increase from the prior year SWK Holdings Corporation Nasdaq: SWKH, a life sciences focused specialty finance company catering to small and mid-sized companies, today provided a business update and announced its financial and operating results for the fourth quarter and full-year ended December 31, 2020. 